Changes in expression of proteoglycan core proteins and heparan sulfate enzymes in the developing and adult murine aorta

Journal of Cardiovascular Translational Research

Volumn 4, Issue 3, 2011, Pages 313-320

  Adhikari, Neeta ^a   Carlson, Marjorie ^a   Lerman, Ben ^a   Hall, Jennifer L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Gene expression; Heparan sulfate; N sulfotransferase; O sulfotransferase; Proteoglycan

Indexed keywords

AGGRECAN; BREVICAN; CORE PROTEIN; DECORIN; EPIMERASE; EXOSTOSIN 1; EXOSTOSIN 2; FIBROBLAST GROWTH FACTOR; GLUCORONYL C5 EPIMERASE; GLYPICAN; GLYPICAN 1; GLYPICAN 3; GLYPICAN 4; HEPARAN SULFATE; HEPARANASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LUMICAN; MESSENGER RNA; N SULFOTRANSFERASE; O SULFOTRANSFERASE; PERLECAN; PROTEOGLYCAN; SULFATASE; SULFOTRANSFERASE; SYNDECAN 1; SYNDECAN 2; SYNDECAN 3; SYNDECAN 4; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERSICAN;

ADULT ANIMAL; ADULTHOOD; ADVENTITIA; ANIMAL TISSUE; AORTA; AORTA DEVELOPMENT; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM; GENE EXPRESSION; MALE; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SMOOTH MUSCLE; SUBENDOTHELIUM;

AGE FACTORS; AGING; ANALYSIS OF VARIANCE; ANIMALS; AORTA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GESTATIONAL AGE; HEPARAN SULFATE PROTEOGLYCANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MURINAE; MUS;

EID: 79960557979     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-011-9261-7     Document Type: Article

References (49)

1. Taylor, K. R., & Gallo, R. L. (2006). Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. The FASEB Journal, 20, 9-22. (Pubitemid 43100470)
2. Forsberg, E., & Kjellen, L. (2001). Heparan sulfate: lessons from knockout mice. Journal of Clinical Investigation, 108, 175-180. (Pubitemid 32656239)
3. Grobe, K., Ledin, J., Ringvall, M., Holmborn, K., Forsberg, E., Esko, J. D., et al. (2002). Heparan sulfate and development: differential roles of the n-acetylglucosamine n-deacetylase/n-sulfotransferase isozymes. Biochimica et Biophysica Acta, 1573, 209-215. (Pubitemid 35335430)
4. Adhikari, N., Basi, D., Rusch, M., Mullegama, S., Larson, J. D., Youseff, J., et al. (2006). Genetic loss of n-sulfation of heparan sulfate alters post golgi trafficking of mcp-1 and remodeling of the vessel wall in response to injury. Circulation Supplement II, 114: II-216
5. MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., et al. (2007). Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of ldl receptor family members. Journal of Clinical Investigation, 117, 153-164. (Pubitemid 46048462)
6. Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000). Vascular-specific growth factors and blood vessel formation. Nature, 407, 242-248.
7. Javerzat, S., Auguste, P., & Bikfalvi, A. (2002). The role of fibroblast growth factors in vascular development. Trends in Molecular Medicine, 8, 483-489.
8. Auguste, P., Javerzat, S., & Bikfalvi, A. (2003). Regulation of vascular development by fibroblast growth factors. Cell and Tissue Research, 314, 157-166. (Pubitemid 37409921)
9. ten Dijke, P., & Arthur, H. M. (2007). Extracellular control of tgfbeta signalling in vascular development and disease. Nature Reviews. Molecular Cell Biology, 8, 857-869. (Pubitemid 47622560)
10. Adhikari, N., Basi, D. L., Townsend, D., Rusch, M., Mariash, A., Mullegama, S., et al. (2010). Heparan sulfate ndst1 regulates vascular smooth muscle cell proliferation, vessel size and vascular remodeling. Journal of Molecular and Cellular Cardiology, 49, 287-293.
11. Fermin, D. R., Barac, A., Lee, S., Polster, S. P., Hannenhalli, S., Bergemann, T. L., et al. (2008). Sex and age dimorphism of myocardial gene expression in nonischemic human heart failure. Circulation: Cardiovascular Genetics, 1, 117-125.
12. Esko, J. D., & Selleck, S. B. (2002). Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annual Review of Biochemistry, 71, 435-71. (Pubitemid 34800227)
13. Holst, C. R., Bou-Reslan, H., Gore, B. B., Wong, K., Grant, D., Chalasani, S., et al. (2007). Secreted sulfatases sulf1 and sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS ONE, 2, e575.
14. Bame, K. J. (2001). Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology, 11, 91R-98R. (Pubitemid 32660349)
15. Nasser, N. (2008). Heparanase involvement in physiology and disease. Cellular and Molecular Life Sciences, 65, 1706-1715.
16. Johnson, P. Y., Potter-Perigo, S., Gooden, M. D., Vernon, R. B., & Wight, T. N. (2007). Decorin synthesized by arterial smooth muscle cells is retained in fibrin gels and modulates fibrin contraction. Journal of Cellular Biochemistry, 101, 281-294. (Pubitemid 46698864)
17. Segev, A., Nili, N., & Strauss, B. H. (2004). The role of perlecan in arterial injury and angiogenesis. Cardiovascular Research, 63, 603-610. (Pubitemid 39078673)
18. Ng, A., Wong, M., Viviano, B., Erlich, J. M., Alba, G., Pflederer, C., et al. (2009). Loss of glypican-3 function causes growth factordependent defects in cardiac and coronary vascular development. Developmental Biology, 335, 208-215.
19. Stepp, M. A., Gibson, H. E., Gala, P. H., Iglesia, D. D., Pajoohesh-Ganji, A., Pal-Ghosh, S., et al. (2002). Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. Journal of Cell Science, 115, 4517-4531. (Pubitemid 36004412)
20. Fukai, N., Kenagy, R. D., Chen, L., Gao, L., Daum, G., & Clowes, A. W. (2009). Syndecan-1: an inhibitor of arterial smooth muscle cell growth and intimal hyperplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 1356-1362.
21. Gotte, M., Bernfield, M., & Joussen, A. M. (2005). Increased leukocyte-endothelial interactions in syndecan-1-deficient mice involve heparan sulfate-dependent and-independent steps. Current Eye Research, 30, 417-422. (Pubitemid 40965522)
22. Stepp, M. A., Daley, W. P., Bernstein, A. M., Pal-Ghosh, S., Tadvalkar, G., Shashurin, A., et al. (2010). Syndecan-1 regulates cell migration and fibronectin fibril assembly. Experimental Cell Research, 316, 2322-2339.
23. Ishiguro, K., Kadomatsu, K., Kojima, T., Muramatsu, H., Nakamura, E., Ito, M., et al. (2000). Syndecan-4 deficiency impairs the fetal vessels in the placental labyrinth. Developmental Dynamics, 219, 539-544.
24. Vikramadithyan, R. K., Kako, Y., Chen, G., Hu, Y., Arikawa-Hirasawa, E., Yamada, Y., et al. (2004). Atherosclerosis in perlecan heterozygous mice. Journal of Lipid Research, 45, 1806-1812. (Pubitemid 40990872)
25. Zhou, Z., Wang, J., Cao, R., Morita, H., Soininen, R., Chan, K. M., et al. (2004). Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Research, 64, 4699-4702. (Pubitemid 38924508)
26. Tran-Lundmark, K., Tran, P.-K., Paulsson-Berne, G., Friden, V., Soininen, R., Tryggvason, K., et al. (2008). Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circulation Research, 103, 43-52.
27. Kinsella, M. G., Tran, P. K., Weiser-Evans, M. C., Reidy, M., Majack, R. A., & Wight, T. N. (2003). Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 608-614. (Pubitemid 36438073)
28. Wight, T. N. (2002). Versican: a versatile extracellular matrix proteoglycan in cell biology. Current Opinion in Cell Biology, 14, 617-623. (Pubitemid 35247746)
29. Mjaatvedt, C. H., Yamamura, H., Capehart, A. A., Turner, D., & Markwald, R. R. (1998). The cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Developmental Biology, 202, 56-66. (Pubitemid 28467247)
30. Henderson, D. J., & Copp, A. J. (1998). Versican expression is associated with chamber specification, septation, and valvulogenesis in the developing mouse heart. Circulation Research, 83, 523-532. (Pubitemid 28411054)
31. Rosenberg, R. D., Shworak, N. W., Liu, J., Schwartz, J. J., & Zhang, L. (1997). Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? The Journal of Clinical Investigation, 99, 2062-2070. (Pubitemid 27203760)
32. Clowes, A. W., Clowes, M. M., Gown, A. M., & Wight, T. N. (1984). Localization of proteoheparan sulfate in rat aorta. Histochemistry, 80, 379-384. (Pubitemid 14100609)
33. Clowes, A. W., & Karnowsky, M. J. (1977). Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature, 265, 625-626. (Pubitemid 8034086)
34. Guyton, J. R., Rosenberg, R. D., Clowes, A. W., & Karnovsky, M. J. (1980). Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circulation Research, 46, 625-634. (Pubitemid 10096678)
35. Lindner, V., & Reidy, M. A. (1991). Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proceedings of the National Academy of Sciences of the United States of America, 88, 3739-3743. (Pubitemid 21916699)
36. Lovich, M. A., & Edelman, E. R. (1999). Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proceedings of the National Academy of Sciences of the United States of America, 96(20), 11111-11116. (Pubitemid 29487342)
37. Rogers, C, Karnovsky, M. J., & Edelman, E. R. (1993). Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation, 88(3), 1215-1221. (Pubitemid 23264041)
38. Welt, F. G, Woods, T. C, & Edelman, E. R. (2001). Oral heparin prevents neointimal hyperplasia after arterial injury: inhibitory potential depends on type of vascular injury. Circulation, 104(25), 3121-3124. (Pubitemid 34014068)
39. Francis, D. J., Parish, C. R, McGarry, M., Santiago, F. S., Lowe, H. C, Brown, K. J., et al. (2003). Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide pi-88: phosphomannopentaose sulfate directly binds fgf-2, blocks cellular signaling, and inhibits proliferation. Circulation Research, 92(8), e70-792.
40. Toyoda, H, Kinoshita-Toyoda, A., Fox, B., & Selleck, S. B. (2000). Structural analysis of glycosaminoglycans in animals bearing mutations in sugarless, sulfateless, and tout-velu. Drosophila homologues of vertebrate genes encoding glycosaminoglycan biosynthetic enzymes. The Journal of Biological Chemistry, 275, 21856-21861. (Pubitemid 30621755)
41. Wang, L., Fuster, M., Sriramarao, P., & Esko, J. D. (2005). Endothelial heparan sulfate deficiency impairs l-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses. Nature Immunology, 6, 902-910. (Pubitemid 43090445)
42. Bullock, S. L., Fletcher, J. M., Beddington, R. S. P., & Wilson, V. A. (1998). Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes & Development, 12, 1894-1906. (Pubitemid 28304341)
43. Li, J.-P. G. F., Hagner-McWhirter, Å., Forsberg, E., Åbrink, M., Kisilevsky, R, Zhang, X., et al. (2003). Targeted disruption of a murine glucuronyl c5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. Journal of Biological Chemistry, 278(31), 28363-28366. (Pubitemid 36935735)
44. Kobayashi, T, Habuchi, H, Tamura, K., Ide, H, & Kimata, K. (2007). Essential role of heparan sulfate 2-o-sulfotransferase in chick limb bud patterning and development. The Journal of Biological Chemistry, 282, 19589-19597. (Pubitemid 47100084)
45. Stanford, K. I., Wang, L., Castagnola, J., Song, D., Bishop, J. R., Brown, J. R., et al. (2010). Heparan sulfate 2-o-sulfotransferase is required for triglyceride-rich lipoprotein clearance. The Journal of Biological Chemistry, 285, 286-294.
46. Takashima, S., Kitakaze, M., Asakura, M., Asanuma, H., Sanada, S., Tashiro, F., et al. (2002). Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 99, 3657-3662. (Pubitemid 34252162)
47. Jones, E. A., Yuan, L., Breant, C., Watts, R. J., & Eichmann, A. (2008). Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos. Development, 135, 2479-2488.
48. Stenvers, K. L., Tursky, M. L., Harder, K. W., Kountouri, N., Amatayakul-Chantler, S., Grail, D., et al. (2003). Heart and liver defects and reduced transforming growth factor {beta}2 sensitivity in transforming growth factor {beta} type III receptor-deficient embryos. Molecular and Cellular Biology, 23, 4371-4385. (Pubitemid 36666437)
49. Compton, L. A., Potash, D. A., Brown, C. B., & Barnett, J. V. (2007). Coronary vessel development is dependent on the type III transforming growth factor beta receptor. Circulation Research, 101, 784-791. (Pubitemid 350287193)